NCT02865616 - MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

March 17, 2020

Study Completion Date

March 17, 2020

Conditions

Clostridium Difficile Infection

Interventions

DRUG

MET-2

Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.

DRUG

Vancomycin

Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.

Trial Locations (1)

T6G2X8

University of Alberta, Edmonton